These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 15135264

  • 21. [Clinical long-term results of H.E.L.P.-apheresis].
    Schuff-Werner P.
    Z Kardiol; 2003; 92(Suppl 3):III28-9. PubMed ID: 14663598
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Highly effective reduction of C-reactive protein in patients with coronary heart disease by extracorporeal low density lipoprotein apheresis.
    Wieland E, Schettler V, Armstrong VW.
    Atherosclerosis; 2002 May; 162(1):187-91. PubMed ID: 11947913
    [Abstract] [Full Text] [Related]

  • 24. How to optimize lipoprotein apheresis treatment--a second look.
    Schettler V, Neumann CL, Hagenah GC, Schulz EG, Wieland E.
    Atheroscler Suppl; 2013 Jan; 14(1):89-92. PubMed ID: 23357148
    [Abstract] [Full Text] [Related]

  • 25. The lipid- and lipoprotein- [LDL-Lp(a)] apheresis techniques. Updating.
    Stefanutti C, Morozzi C, Perrone G, Di Giacomo S, Vivenzio A, D'Alessandri G.
    G Chir; 2012 Jan; 33(11-12):444-9. PubMed ID: 23140934
    [Abstract] [Full Text] [Related]

  • 26. Indication of low-density lipoprotein apheresis in severe hypercholesterolemia and its atherosclerotic vascular complications: dextran sulfate cellulose low-density lipoprotein apheresis.
    Keller C.
    Ther Apher Dial; 2003 Jun; 7(3):345-9. PubMed ID: 12924611
    [Abstract] [Full Text] [Related]

  • 27. Low-density lipoprotein apheresis using the Liposorber dextran sulfate cellulose system for patients with hypercholesterolemia refractory to medical therapy.
    Gordon BR, Saal SD.
    J Clin Apher; 1996 Jun; 11(3):128-31. PubMed ID: 8915816
    [Abstract] [Full Text] [Related]

  • 28. Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia.
    Græsdal A, Bogsrud MP, Holven KB, Nenseter MS, Narverud I, Langslet G, Brekke M, Retterstøl K, Arnesen KE, Ose L.
    J Clin Lipidol; 2012 Jun; 6(4):331-9. PubMed ID: 22836070
    [Abstract] [Full Text] [Related]

  • 29. Regression of coronary atherosclerosis and amelioration of renal function during LDL-immunoadsorption therapy in a renal transplant recipient.
    Jansen M, Gabriel H, Banyai S, Pidlich J, Weidinger F, Hörl WH, Derfler K.
    Wien Klin Wochenschr; 1996 Jun; 108(14):425-31. PubMed ID: 8784984
    [Abstract] [Full Text] [Related]

  • 30. [The effect of LDL-apheresis on the long-term prognosis of hypercholesterolemic patients with coronary artery bypass grafts: a multicenter study].
    Kito Y, Takahashi J, Endo M, Agishi T, Kitamura S, Matsuda H, Fujiwara T, Dohi T, Ito T, Kawashima Y.
    Kyobu Geka; 1993 May; 46(5):399-404. PubMed ID: 8492490
    [Abstract] [Full Text] [Related]

  • 31. LDL-apheresis reduces P-Selectin, CRP and fibrinogen -- possible important implications for improving atherosclerosis.
    Kobayashi S, Oka M, Moriya H, Maesato K, Okamoto K, Ohtake T.
    Ther Apher Dial; 2006 Jun; 10(3):219-23. PubMed ID: 16817784
    [Abstract] [Full Text] [Related]

  • 32. State of the art of low-density lipoprotein apheresis in the year 2003.
    Bosch T, Wendler T.
    Ther Apher Dial; 2004 Apr; 8(2):76-9. PubMed ID: 15255120
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Extracorporal low-density lipoprotein elimination by immunoadsorption.
    Ritter MM, Parhofer KG.
    Ther Apher Dial; 2003 Jun; 7(3):370-2. PubMed ID: 12924615
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Efficacy and safety of DALI LDL-apheresis at high blood flow rates: a prospective multicenter study.
    Wendler T, Schilling R, Lennertz A, Sodemann K, Kleophas W, Messner H, Riechers G, Wagner J, Keller C, Bosch T.
    J Clin Apher; 2003 Jun; 18(4):157-66. PubMed ID: 14699591
    [Abstract] [Full Text] [Related]

  • 37. [Effects of LDL-apheresis--more than reduction of cholesterol?].
    Schettler V, Wieland E.
    Dtsch Med Wochenschr; 2007 Mar 16; 132(11):575-8. PubMed ID: 17342636
    [Abstract] [Full Text] [Related]

  • 38. Is lipoprotein (a)-apheresis useful?
    Bambauer R.
    Ther Apher Dial; 2005 Apr 16; 9(2):142-7. PubMed ID: 15828926
    [Abstract] [Full Text] [Related]

  • 39. Effect of low-density lipoprotein apheresis on patients with peripheral arterial disease. Peripheral Arterial Disease LDL Apheresis Multicenter Study (P-LAS).
    Tsuchida H, Shigematsu H, Ishimaru S, Iwai T, Akaba N, Umezu S.
    Int Angiol; 2006 Sep 16; 25(3):287-92. PubMed ID: 16878078
    [Abstract] [Full Text] [Related]

  • 40. Direct adsorption of lipoproteins (DALI) from whole blood: first long-term clinical experience with a new LDL-apheresis system for the treatment of familial hypercholesterolaemia.
    Jansen M, Banyai S, Schmaldienst S, Goldammer A, Rohac M, Hörl WH, Derfler K.
    Wien Klin Wochenschr; 2000 Jan 28; 112(2):61-9. PubMed ID: 10703153
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.